Expert Interview
Discussing the future Multiple Myeloma treatment landscape following multiple datasets presented at ASH 2025 including Iberdomide, CARVYKTI, and anito-cel.
Ticker(s): BMY, JNJ, GILDInstitution: Fred Hutchinson Cancer Research Center & Univ. of Washington
- Hematologist and Medical Oncologist at Fred Hutch & Associate Professor, Department of Medical Oncology.
- Treats 20-30 cases of refractory gastrointestinal acute graft-versus-host disease per year, 100 patients with CLL and 60 patients with r/r DLBCL.
- Research focuses on improving outcome for patients with multiple myeloma, non-Hodgkin's lymphoma, and Hodgkin's disease using autologous transplant techniques.
On a scale of 1 to 10 how would you rate your excitement for BMS' Iberdomide?
Added By: max_adminOn a scale of 1 to 10 how would you rate your excitement for Johnson & Johnson' CARVYKTI?
Added By: max_adminOn a scale of 1 to 10 how would you rate your excitement for Gilead's anitocabtagene autoleucel?
Added By: max_adminAre You Interested In These Questions?
Slingshot Insights Explained
- Call Date
- Jan 15, 2026
- Call Time
- 05:00 PM EST
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
